Introduction/Background Cervical cancer is a leading cause of morbidity and mortality for women worldwide. Concurrent chemotherapy alongside radiotherapy are the standard treatment for this neoplasm.

This study aimed to identify the disease-free and overall survivals of patients with locally advanced cervical cancer (LACC) treated with concurrent chemoradiotherapy (CT-RT).

Methodology We conducted a retrospective study at Salah Azaiez Institute of Oncology from January 1, 2010, to December 31, 2020, including 19 patients treated with concurrent chemoradiotherapy for LACC with complete response. The overall survival rate (OS) and disease-free survival (DFS) rate were estimated using the Kaplan–Meier method. Prognosis-related risk factors were analyzed using univariate analyses.

Results 19 patients diagnosed with LACC were treated with curative intention using concurrent chemoradiotherapy with complete response. In 7 cases (36.8%) FIGO stage was ≤IIB and in 12 cases (63.2%) FIGO stage was ≥IIIA. Among these patients, 3 presented loco-regional recurrence, and one presented regional recurrence associated with distant metastases. Two-year DFS was 82%. Cell type (p=0.000), lymphovascular space involvement (LVSI) (p=0.000), and FIGO stage (p=0.025) were prognostic factors that affected disease-free survival. DFS was not significantly different for tumor size (p=0.497), parametrial invasion (p=0.468), and pelvic lymph node metastases on MRI (p=0.060). Two-year OS was 94.4%. Parametrial invasion (p=0.000) and paraaortic lymph node metastases on MRI (p=0.020) were prognostic factors that affected Overall survival. OS was not significantly different for cell type (p=0.122), tumor size (p=0.106), parametrial invasion (p=0.096), and lymphovascular involvement (p=0.627).

Conclusion Cell type, lymphovascular space involvement, and FIGO stage were prognostic factors for DFS, while parametrial invasion and paraaortic lymph node metastases on MRI were prognostic factors for OS in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy with complete response.

Disclosures We have no potential conflict of interest to report